Suchitra Sundaram, MD, shares that ASH 2025 presented major advances in chronic lymphocytic leukemia (CLL) across both time‑limited and continuous treatment strategies, and emphasized the growing role ...

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective time-limited therapy options. Marc S. Hoffmann, MD, highlights 3-year results from ...

An opinion paper published in Medical Oncology outlined the most important criteria to keep in mind and how to prioritize them during treatment decision making. Carda ...

Zanubrutinib demonstrates prolonged progression-free survival in relapsed/refractory CLL/SLL, with a median PFS of 52.5 months and 49.9 months for patients with del17p. The ALPINE trial confirms ...

Two years after premiering a 13-minute documentary about three eczema patients, Abbvie has again teamed with branded entertainment firm Passion Point Collective, this time for a 16-minute documentary ...

A Celebration of Patsy Ruth Eastham’s Life, age 94, of Jasper, Texas, will be at 11:00 a.m., Tuesday, December 23, 2025 at Stringer & Griffin Funeral Home, Jasper, Texas with burial to follow at ...

Credit: Getty Images The latest data released at ASH 2025 highlight how targeted therapies are changing the way CLL is managed. Significant treatment options with targeted therapies are changing the ...

Combining CIT with BTKi may enhance complete response rates and progression-free survival in RT-DLBCL compared to CIT alone. The study observed no statistically significant difference in overall ...